ThinkEquity Assumes Optimer Pharma (OPTR) at Buy, Sets $25 Price Target
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 60
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 60
Join SI Premium – FREE
ThinkEquity's James Molloy assumed coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Buy rating and $25 price target Monday morning.
The stock is up about 1.2 percent to $15.22 at last check.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
The stock is up about 1.2 percent to $15.22 at last check.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BWS Financial Starts Twist Bioscience (TWST) at Sell, 'Insider selling activity picked up steam'
- Leerink Starts Amneal Pharmaceuticals (AMRX) at Outperform
- Freedom Capital Starts Pulse Biosciences (PLSE) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
ThinkEquitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
